Multiply Labs, Inc.

Based in the US, Multiply Labs, Inc. is a robotics company focused on the manufacturing of precision medicines through advanced automation technologies. Based in San Francisco, US, and founded in 2016 by co-founders Fred Parietti and Alice Melocchi, Multiply Labs, Inc. specializes in developing robotic systems for the industrial-scale manufacturing of gene-modified cell therapies.

In April 2021, Multiply Labs, Inc. raised USD 25. 04 million in series A funding led by investor Casdin Capital, with participation from other investors Founders Fund and Lux Capital, Fifty Years, and Garage Capital. The Series A funding values Multiply Labs, Inc.

at USD 60 million post-money. Multiply Labs develops advanced robotic systems designed for the manufacturing of precision medicines, particularly gene-modified cell therapies, at an industrial scale. Their technology streamlines production processes in the life sciences sector, offering a modular platform that enables high-throughput capabilities through tailored robotic modules. The company caters to a diverse clientele in biotechnology and pharmaceuticals, focusing on markets in North America, Europe, and Asia.

Multiply Labs generates revenue primarily through partnerships and subscription models with biotechnology and pharmaceutical firms. Their transactions revolve around the sale or leasing of robotic manufacturing systems supported by service agreements, including digital process control and maintenance. Their core offerings, such as Digital Quality Control systems and cell therapy capsules, are integrated into clients' production lines, ensuring compliance with Good Manufacturing Practices.